[1]
|
World Health Organization (WHO) (2022) Hepatitis B 2022. https://www.who.int/zh/news-room/fact-sheets/detail/hepatitis-b
|
[2]
|
Polaris Observatory Collaborators (2018) Global Prevalence, Treatment, and Prevention of Hepatitis B Virus Infection in 2016: A Modelling Study. The Lancet. Gastroenterology & Hepatology, 3, 383-403.
|
[3]
|
Schweitzer, A., Horn, J, Mikolajczyk, R.T., et al. (2015) Estimations of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: A Systematic Review of Data Published Between 1965 and 2013. Lancet, 386, 1546-1555. https://doi.org/10.1016/S0140-6736(15)61412-X
|
[4]
|
Lim, Y.S. (2024) Gray Zone of Hepatitis B Virus Infection. Saudi Journal of Gastroenterology, 30, 76-82. https://doi.org/10.4103/sjg.sjg_279_23
|
[5]
|
Terrault, N.A., Lok, A.S.F., McMahon, B.J., et al. (2018) Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 67, 1560-1599. https://doi.org/10.1002/hep.29800
|
[6]
|
European Association for the Study of the Liver (2017) EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398. https://doi.org/10.1016/j.jhep.2017.03.021
|
[7]
|
王贵强, 王福生, 庄辉, 等. 慢性乙型肝炎防治指南(2019年版) [J]. 中国肝脏病杂志, 2019, 11(4): 5-27.
|
[8]
|
尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版) [J]. 实用肝脏病杂志, 2023, 26(3): 457-478.
|
[9]
|
陈园生, 梁晓峰, 胡俊峰, 等. 乙型肝炎病毒感染血清学标志与慢性感染自然史研究进展[J]. 中国疫苗和免疫, 2009, 15(3): 279-283.
|
[10]
|
Huang, D.Q., Li, X, Le, M.H., et al. (2022) Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients with Indeterminate Phase. Clinical Gastroenterology and Hepatology, 78, 1558-1568.
|
[11]
|
Hsu, Y.N., Pan, C.Q, Abbasi, A., et al. (2014) Clinical Presentation and Disease Phases of Chronic Hepatitis B Using Conventional versus Modified ALT Criteria in Asian Americans. Digestive Diseases and Sciences, 59, 865-871. https://doi.org/10.1007/s10620-014-3054-1
|
[12]
|
Di Bisceglie, A.M., Lombardero, M., Teckman, J., et al. (2017) Determination of Hepatitis B Phenotype Using Biochemical and Serological Markers. Journal of Viral Hepatitis, 24, 320-329. https://doi.org/10.1111/jvh.12643
|
[13]
|
Vinikoor, M.J., Sinkala, E., Kanunga, A., et al. (2018) Chronic Hepatitis B Virus Monoinfection at a University Hospital in Zambia. World Journal of Hepatology, 10, 622-628. https://doi.org/10.4254/wjh.v10.i9.622
|
[14]
|
Yao, K., Liu, J, Wang, J., et al. (2021) Distribution and Clinical Characteristics of Patients with Chronic Hepatitis B Virus Infection in the Grey Zone. Journal of Viral Hepatitis, 28, 1025-1033. https://doi.org/10.1111/jvh.13511
|
[15]
|
Xu, X., Wang, H., Shan, S., et al. (2023) The Impact of the Definitions of Clinical Phases on the Profiles of Grey-Zone Patients with Chronic Hepatitis B Virus Infection. Viruses, 15, Article 1212. https://doi.org/10.3390/v15051212
|
[16]
|
Jiang, S.W., Lian, X., Hu, A.R., et al. (2023) Liver Histopathological Lesions Is Severe in Patients with Normal Alanine Transaminase and Low to Moderate Hepatitis B Virus DNA Replication. World Journal of Gastroenterology, 29, 2479-2494. https://doi.org/10.3748/wjg.v29.i16.2479
|
[17]
|
周璇, 李维正, 马文婷, 等. ALT正常慢性HBV感染者肝组织病理与年龄、ALT和HBV DNA水平相关性研究[J]. 肝脏, 2019, 24(10): 1141-1144.
|
[18]
|
王兴飞, 沈华江, 许文芳. ALT持续正常的慢性HBV感染患者肝脏病理特点分析[J]. 中华全科医学, 2019, 17(2): 238-240, 309.
|
[19]
|
Spradling, P.R., Xing, J, Rupp, L.B., et al. (2016) Distribution of Disease Phase, Treatment Prescription and Severe Liver Disease among 1598 Patients with Chronic Hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013. Alimentary Pharmacology & Therapeutics, 44, 1080-1089. https://doi.org/10.1111/apt.13802
|
[20]
|
Lee, H.W., Kim, S.U, Baatarkhuu, O., et al. (2019) Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. Clinical Gastroenterology and Hepatology, 17, 2808-2810.E2. https://doi.org/10.1016/j.cgh.2019.01.002
|
[21]
|
张雪莲. 慢性HBV感染孕妇的乙肝自然史分期及其与母婴妊娠结局的关系[D]: [硕士学位论文]. 广州: 南方医科大学, 2023.
|
[22]
|
Choi, G.H., Kim, G.A, Choi, J., et al. (2019) High Risk of Clinical Events in Untreated HBeAg-Negative Chronic Hepatitis B Patients with High Viral Load and No Significant ALT Elevation. Alimentary Pharmacology & Therapeutics, 50, 215-226. https://doi.org/10.1111/apt.15311
|
[23]
|
Hsu, Y.C., Chen, C.Y., Chang, I.W., Chang, C.Y., Wu, C.Y., Lee, T.Y., et al. (2021) Once-Daily Tenofovir Disoproxil Fumarate in Treatment-Naive Taiwanese Patients with Chronic Hepatitis B and Minimally Raised Alanine Aminotransferase (TORCH-B): A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group, Randomised Trial. The Lancet Infectious Diseases, 21, 823-833. https://doi.org/10.1016/S1473-3099(20)30692-7
|
[24]
|
Ford, N., Scourse, R., Lemoine, M., et al. (2018) Adherence to Nucleos(T)Ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. Hepatology Communications, 2, 1160-1167. https://doi.org/10.1002/hep4.1247
|
[25]
|
Papatheodoridis, G.V., Manolakopoulos, S, Liaw, Y.F., et al. (2012) Follow-Up and Indications for Liver Biopsy in HBeAg-Negative Chronic Hepatitis B Virus Infection with Persistently Normal ALT: A Systematic Review. Journal of Hepatology, 57, 196-202. https://doi.org/10.1016/j.jhep.2011.11.030
|
[26]
|
Bonacci, M., Lens, S, Mariño, Z., et al. (2018) Anti-Viral Therapy Can Be Delayed or Avoided in a Significant Proportion of HBeAg-Negative Caucasian Patients in the Grey Zone. Alimentary Pharmacology & Therapeutics, 47, 1397-1408. https://doi.org/10.1111/apt.14613
|
[27]
|
Oliveri, F., Surace, L., Cavallone, D., et al. (2017) Long-Term Outcome of Inactive and Active, Low ViraemicHBeAg-Negative-Hepatitis B Virus Infection: Benign Course towards HBsAg Clearance. Liver International, 37, 1622-1631. https://doi.org/10.1111/liv.13416
|
[28]
|
中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30(2): 131-136.
|